---
title: "Radiopharm Theranostics Limited (RADX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/RADX.US.md"
symbol: "RADX.US"
name: "Radiopharm Theranostics Limited"
industry: "生物技术"
---

# Radiopharm Theranostics Limited (RADX.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.radiopharmtheranostics.com](https://www.radiopharmtheranostics.com) |

## Company Profile

Radiopharm Theranostics Limited 是一家临床阶段的放射治疗公司，专注于研发用于诊断和治疗的放射性药物，主要针对医疗需求未得到满足的领域。该公司开发了多种产品，包括 RAD101，一种用于脑转移的 pivalate 诊断药物；RAD102，一种 pivalate 治疗药物；RAD201a，一种 Nano-mAb HER-2 乳腺诊断药物；RAD202，一种 Nano-mAb HER-2 乳腺治疗药物；RAD203，一种 Nano-mAb PDL1 非小细胞肺癌诊断药物；以及 RAD204，一种 Nano-mAb PDL1 非小细胞肺癌治疗药物。此外，公司还在开发 R...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-03-02T04:30:15.000Z

**Overall: C (0.54)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 149 / 406 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4796.06% |  |
| Net Profit YoY | -7.72% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.70 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 58.95M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 10.65M |  |


**Multi Score**: C

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -88.74% | E |
| Profit Margin | -286.16% | E |
| Gross Margin | -264.28% | E |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4796.06% | A |
| Net Profit YoY | -7.72% | C |
| Total Assets YoY | 6.13% | B |
| Net Assets YoY | 3.35% | C |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -34.95% | D |
| OCF YoY | 4796.06% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.18 | D |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 45.22% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Radiopharm Theranostics Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-88.74%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-286.16%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-264.28%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "4796.06%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-7.72%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.13%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "3.35%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-34.95%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "4796.06%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.18",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "45.22%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 03 | MiMedx (US.MDXG) | A | B | A | B | B | A |
| 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.93 | 250/606 | - | - | - |
| PB | 1.70 | 146/606 | 1.67 | 1.35 | 1.06 |
| PS (TTM) | 5.53 | 105/606 | 173.40 | 139.08 | 5.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-10T05:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 3 | 60% |
| Overweight | 1 | 20% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.99 |
| Highest Target | 30.43 |
| Lowest Target | 13.04 |

## References

- [Company Overview](https://longbridge.com/en/quote/RADX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/RADX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/RADX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.